Blood Magnesium Levels in Migraine

Schoenen, Jean; Sianard-Gainko, J.; Lenaerts, Marc

doi:10.1046/j.1468-2982.1991.1102097.x

Cited by 66 publications

(48 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Migraine has been linked to low levels of magnesium in serum and cerebrospinal fluid (CSF) (414,457). Migraine headaches are the consequence of cortical spreading depression (CSD), which consists of an intense membrane depolarization and repolarization in neurons and glial cells (308,388).…”

Section: Migrainementioning

confidence: 99%

Magnesium in Man: Implications for Health and Disease

Baaij

Hoenderop

Bindels

2015

Physiological Reviews

1,285

1,299

View full text Add to dashboard Cite

show abstract

Section: Migrainementioning

confidence: 99%

Magnesium in Man: Implications for Health and Disease

Baaij

Hoenderop

Bindels

2015

Physiological Reviews

1,285

1,299

View full text Add to dashboard Cite

show abstract

“…Electrophysiological studies using TMS indicate contradictory results [for review, see (11)(12)(13)]. However, several lines of evidence regarding biochemical data (14)(15)(16), familial hemiplegic migraine (FHM) (17) as well as cortical spreading depression (CSD), which is responsible for the aura symptoms in migraine (18,19), support the hypothesis of cortical hyperexcitability in migraine. Clarke et al (20) have demonstrated a reduction of pain intensity by TMS administered immediately after the onset of migraine headaches.…”

Section: Introductionmentioning

confidence: 99%

Low-frequency rTMS of the vertex in the prophylactic treatment of migraine

et al. 2009

View full text Add to dashboard Cite

High-frequency repetitive transcranial magnetic stimulation (rTMS) increases and low-frequency rTMS decreases neural excitability. Clinically, rTMS shows beneficial effects in the treatment of neurological and psychiatric disorders. Furthermore, chronic and neuropathic pain has been shown to respond to rTMS treatment. A small pilot study revealed prophylactic effects of high-frequency rTMS in migraine. As there is evidence of neuronal hyperexcitability in migraine, we conducted a placebo-controlled, blinded study to evaluate the therapeutic effects of low-frequency rTMS in migraine. The primary end-point was defined as a reduction of migraine attacks compared with placebo, secondary outcomes were a reduction in the total number of days with headache, hours with headache, pain intensity and a decrease of analgesic intake for migraine. Twenty-seven migraineurs completed the study and were treated with rTMS on five consecutive days. For the verum group, two trains of 500 pulses with a frequency of 1 Hz were applied over vertex with a round coil. For the treatment of the placebo group, a figure-of-eight sham coil was used. A significant decrease of migraine attacks could be observed in the verum group. However, when comparing these effects with placebo, no significance was evident. The same was true concerning secondary outcome measures with regard to days with migraine and total hours with migraine. No effects were evident for pain intensity and use of analgesics. The rTMS treatment was tolerated well. rTMS stimulation over vertex with 1 Hz was not effective in migraine prophylaxis when compared with placebo. The positive effects regarding migraine attacks, days and total hours with migraine in the verum group are encouraging and indicate that further research on this topic is warranted.

show abstract

“…In 1976, Durlach [1] found increased concentration of magnesium in the urine of migraine patients and presumed it to be a result of a transitory serum magnesium decrease in migraine attack. This hypothesis was further corroborated by the observations that in migraine patients intracellular magnesium was reduced during attacks in the brain [2], serum [3,4] and saliva [4], and between attacks in blood [5], erythrocytes, mononuclear cells [6,7] and cerebrospinal fluid [8]. However, several studies did not confirm these findings [9,10].…”

Section: Introductionmentioning

confidence: 79%

Efficacy of intravenous magnesium sulfate in severe migraine attacks

Zidverc-Trajković¹,

Pavlović²,

Jovanović³

et al. 2001

J Headache Pain

View full text Add to dashboard Cite

IntroductionA possible link between magnesium deficiency and some types of headache, particularly migraine, has long been suggested. In 1976, Durlach [1] found increased concentration of magnesium in the urine of migraine patients and presumed it to be a result of a transitory serum magnesium decrease in migraine attack. This hypothesis was further corroborated by the observations that in migraine patients intracellular magnesium was reduced during attacks in the brain [2], serum [3,4] and saliva [4], and between attacks in blood [5], erythrocytes, mononuclear cells [6,7] and cerebrospinal fluid [8]. However, several studies did not confirm these findings [9,10]. Therefore, Ferrari and Bach [11] concluded that although "no consistent pattern can be detected with respect to circulating magnesium levels in migraine patients", magnesium in the brain might be involved in migraine pathophysiology.Several trials of intravenously administered magnesium in the treatment of headache attacks (including migraine) were conducted with a wide spectrum of results, ranging from very enthusiastic [12-14] to highly disappointing [15]. Therefore, the aim of this open study was to estimate the efficacy of intravenous magnesium sulfate (1 g) in the treatment of severe migraine attacks. Abstract The aim of this open study was to make a preliminary estimate of the efficacy and tolerability of intravenously administered magnesium sulfate (1 g) in comparison to subcutaneously administered sumatriptan in the treatment of severe migraine attacks. The study comprised 22 consecutive patients whose attacks were treated with magnesium sulfate (5 ml of a 20% solution), and the results were compared with those of another group of 14 consecutive patients whose attacks were treated with sumatriptan (6 mg). Immediately before and 10, 20 and 30 minutes after injections, patients reported pain intensity on a verbal 0-10 scale. Pain disappearance or pain relief >50% were considered significant. Efficacy of sumatriptan was superior that of to magnesium sulfate 20 minutes after the injections (p<0.05) and comparable after 30 minutes (magnesium therapy was successful in 68% in comparison to 79% of patients treated with sumatriptan). After only 10 minutes, 3 patients treated with magnesium sulfate were pain free, with the same effect in 5 (22.5%) and 10 (45%) patients after 20 and 30 minutes, respectively. The rate of headache recurrence was low and no major adverse effects were recorded. In conclusion, magnesium sulfate may be a well-tolerated pharmacological alternative for the treatment of severe migraine attacks.

show abstract

Blood Magnesium Levels in Migraine

Cited by 66 publications

References 3 publications

Magnesium in Man: Implications for Health and Disease

Magnesium in Man: Implications for Health and Disease

Low-frequency rTMS of the vertex in the prophylactic treatment of migraine

Efficacy of intravenous magnesium sulfate in severe migraine attacks

Contact Info

Product

Resources

About